Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03268213 · ClinicalTrials.gov registry record · Early Phase 1
Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis
A Early Phase 1 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT03268213 is a Early Phase 1 study that has completed, run by Stony Brook University. The registered enrollment target is 12 participants.
The verdict
NCT03268213, a Early Phase 1 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Fecal Microbiota Transplantation will be offered to eligible C. difficile patients (does not require Investigational New Drug designation) and to eligible ulcerative colitis or indeterminate colitis patients as Investigational New Drug treatment
Interventions
- BIOLOGICAL Fecal Microbial Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-11 |
| Est. Completion | 2022-02-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03268213
The ClinicalTrials.gov registry entry for NCT03268213 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fecal Microbial Transplantation is the first listed.
NCT03268213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03268213 about?
NCT03268213 is a clinical study titled "Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis". Fecal Microbiota Transplantation will be offered to eligible C. difficile patients (does not require Investigational New Drug designation) and to eligible ulcerative colitis or indeterminate colitis patients as Investigational New Drug treatment
What is the current status of trial NCT03268213?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2013-11. Estimated completion is 2022-02-15.
What interventions are being tested in trial NCT03268213?
The interventions under investigation include: Fecal Microbial Transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT03268213?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.